GNFT

MKT CAP:$446M

Genfit S.A.

Market Cap

$446M

Healthcare·Biotechnology·🇫🇷 France·NASDAQ

Healthcare·Biotechnology·🇫🇷·NASDAQ

Stock Price

$5.97-$0.06 (-1.00%)

Jan 20, 2026

Company Details

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat pati...

CEO

M. Pascal Prigent

IPO Date

Mar 27, 2019

Website

www.genfit.com

Key Metrics TTM

Revenue

$133M

+27.4% YoY

Net Income

-$34M

EPS (Diluted)

-$0.82

Free Cash Flow

-$52M

Revenue / Share

$2.68

Gross Margin

103.7%

Operating Margin

-17.9%

Net Margin

-25.7%

FCF Margin

-38.8%

P/S

3.3x

P/E

—

Earnings Reports

Q2 2025

Jun 30, 2025

$42M-41.8%EPS -$0.23

FY 2024

Apr 29, 2025

$78M+134.6%EPS $0.04

Q4 2024

Apr 29, 2025

$7MEPS -$0.68

Q2 2024

Sep 19, 2024

$71M+432.2%EPS $0.58

FY 2023

Apr 5, 2024

$33M+41.4%EPS -$0.68

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 16	$4M	$3M	-$25M
Q2 17	$5M	$5M	-$26M
Q4 17	$3M	$2M	-$40M
Q2 18	$6M	$6M	-$37M
Q4 18	$3M	$3M	-$44M
Q2 19	$6M	$6M	-$54M
Q4 19	$36M	$39M	-$12M
Q2 20	$142.6K	$7M	-$64M
Q4 20	$751.8K	$3M	-$37M
Q2 21	$12.9K	$4M	-$37M
Q4 21	$94M	$96M	$69M
Q2 22	$10M	$14M	-$20M
Q2 23	$13M	$18M	-$28M
Q2 24	$71M	$71M	$37M
Q4 24	$7M	$8M	-$33M
Q2 25	$42M	$42M	$88.9K

Valuation

Quarter	P/S	P/E
Q4 16	59.0x	—
Q2 17	48.8x	—
Q4 17	47.6x	—
Q2 18	42.9x	—
Q4 18	44.8x	—
Q2 19	43.8x	—
Q4 19	15.2x	—
Q2 20	4.7x	—
Q4 20	4.5x	—
Q2 21	4.6x	—
Q4 21	2.6x	—
Q2 22	1.6x	16.4x
Q2 23	1.6x	4.4x
Q2 24	1.1x	3.0x
Q4 24	1.8x	—
Q2 25	1.4x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 16	-$16M	-$18M
Q2 17	-$30M	-$32M
Q4 17	-$28M	-$30M
Q2 18	-$37M	-$38M
Q4 18	-$29M	-$31M
Q2 19	-$55M	-$55M
Q4 19	-$6M	-$9M
Q2 20	-$57M	-$58M
Q4 20	-$63M	-$63M
Q2 21	-$33M	-$34M
Q4 21	$148M	$148M
Q2 22	-$57M	-$57M
Q2 23	-$30M	-$33M
Q2 24	-$13M	-$14M
Q4 24	$31M	$31M
Q2 25	-$35M	-$36M

Capital Expenditures

Quarter	CapEx
Q4 16	$2M
Q2 17	$1M
Q4 17	$2M
Q2 18	$1M
Q4 18	$2M
Q2 19	$76.0K
Q4 19	$2M
Q2 20	$917.8K
Q4 20	$134.5K
Q2 21	$24.6K
Q4 21	$603.3K
Q2 22	$0
Q2 23	$2M
Q2 24	$861.7K
Q4 24	$282.9K
Q2 25	$1M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 16	-0.7%	+118.3%
Q2 17	+95.9%	+135.0%
Q4 17	+18.6%	+250.4%
Q2 18	+41.0%	+122.9%
Q4 18	-20.5%	+65.5%
Q2 19	+15.9%	+90.0%
Q4 19	+1278.5%	+12.4%
Q2 20	-97.6%	+49.2%
Q4 20	-73.7%	-19.1%
Q2 21	-99.8%	-38.6%
Q4 21	+159.6%	-48.0%
Q2 22	+7104.9%	-51.9%
Q2 23	+1685.7%	+7.8%
Q2 24	+555372.7%	-5.1%
Q4 24	-92.6%	+58.3%
Q2 25	+304.3%	+34.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 16	$12.9K	0.4%
Q2 17	$150.8K	2.8%
Q4 17	$174.2K	6.7%
Q2 18	$316.8K	5.4%
Q4 18	$603.3K	21.1%
Q2 19	$416.2K	6.7%
Q4 19	$2M	4.2%
Q2 20	$599.8K	420.5%
Q4 20	$845.3K	112.4%
Q2 21	$253.7K	1972.7%
Q4 21	$295.8K	0.3%
Q2 22	$173.0K	1.7%
Q2 23	$320.4K	2.4%
Q2 24	$390.5K	0.5%
Q4 24	$0	0.0%
Q2 25	$282.9K	0.7%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q4 16	$24M	$4M	—
Q2 17	$28M	$4M	—
Q4 17	$36M	$7M	—
Q2 18	$38M	$5M	—
Q4 18	$41M	$5M	$838.3K
Q2 19	$45M	$11M	$3M
Q4 19	$32M	$9M	$13M
Q2 20	$41M	$10M	$11M
Q4 20	$26M	$7M	$2M
Q2 21	$27M	$9M	$915.5K
Q4 21	$13M	$10M	$883.9K
Q2 22	$20M	$10M	$537.8K
Q2 23	$29M	$11M	$608.0K
Q2 24	$22M	$12M	$456.0K
Q4 24	$35M	$10M	—
Q2 25	$29M	$12M	$458.3K

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 17	$320M	$0	$320M
Q2 18	$278M	$0	$278M
Q4 18	$242M	$0	$242M
Q2 19	$330M	$0	$330M
Q4 19	$324M	$0	$324M
Q2 20	$264M	$0	$264M
Q4 20	$200M	$0	$200M
Q2 21	$122M	$0	$122M
Q4 21	$303M	$0	$303M
Q2 22	$244M	$0	$244M
Q4 22	$159M	$5M	$164M
Q2 23	$131M	$0	$131M
Q4 23	$91M	$0	$91M
Q2 24	$72M	$0	$72M
Q4 24	$96M	$0	$96M
Q2 25	$126M	$0	$126M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 16	28M	+9.8%	+19.9%
Q2 17	31M	+10.9%	+30.1%
Q4 17	31M	+0.0%	+30.1%
Q2 18	31M	0.0%	+21.7%
Q4 18	31M	+0.0%	+10.9%
Q2 19	31M	+0.1%	+0.1%
Q4 19	39M	+24.5%	+24.5%
Q2 20	39M	-0.0%	+24.5%
Q4 20	39M	-0.0%	+24.5%
Q2 21	48M	+22.9%	+52.9%
Q4 21	57M	+19.8%	+47.1%
Q2 22	50M	-13.0%	+28.0%
Q2 23	50M	+0.1%	+28.1%
Q2 24	60M	+21.5%	+26.6%
Q4 24	50M	-17.7%	-13.0%
Q2 25	50M	+0.2%	+0.2%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 16	—	—
Q2 17	—	—
Q4 17	—	—
Q2 18	—	—
Q4 18	—	—
Q2 19	—	—
Q4 19	$185.9K	194
Q2 20	$735	194
Q4 20	$5.8K	130
Q2 21	$99	130
Q4 21	$767.2K	122
Q2 22	$84.2K	122
Q2 23	$90.7K	148
Q2 24	$449.3K	159
Q4 24	$38.3K	180
Q2 25	$230.8K	180

Revenue / Employee